Veidlapa Nr. M-3 (8)

Study Course Description

Principles of Treatment of Haematological Diseases

Main Study Course Information

Course Code

RHE_054

Branch of Science

Clinical medicine

ECTS

9.00

Target Audience

Medicine

LQF

Level 8

Study Course Implementer

Course Supervisor

Sandra Lejniece

Residency Speciality

Speciality

Hematologist

Supervisor of Medical Speciality

Sandra Lejniece

Contacts

About Study Course

Objective

To ensure acquisition and improvement of theoretical knowledge and practical skills in the principles of treatment of hematological diseases in accordance with the requirements of the haematology specialty in order to prepare the doctor for certification in the haematology specialty.

Learning Outcomes

Knowledge

1.- Knows about cytostatic drugs, their groups, principles of action; principles of treatment; - Knows about early and late complications of chemotherapy drugs; - Knows about the principles of radiotherapy in cases of haematological pathologies; - Knows about therapeutic monoclonal antibodies, their application in haematology; - Knows about haematological malignancies during pregnancy; - Knows about prescribing immunosuppressive drugs and growth factors in cases of haematological tumours.

Skills

1.- Will be able to prescribe cytostatic drugs, radiotherapy and monoclonal antibodies to haematological patients.

Competences

1.Prescription of cytostatic drugs, radiotherapy and monoclonal antibodies to haematological patients.

Assessment

Individual work

Title	% from total grade	Grade
1. Individual work	-	-
1. Independently studies the literature related to the course topics; 2. Independently prepares for seminars; 3. Gets acquainted with and analyses medical documentation; 4. Completes medical documentation; 5. Independently follows the instructions of the certified specialist.

Examination

Title	% from total grade	Grade
1. Examination	-	-
Mandatory attendance of seminars (100%) and performance of practical work (100%) in each study course.

Study Course Theme Plan

FULL-TIME

Part 1

Seminar

Modality	Location
-	-

Topics

Cytostatic or chemotherapy drugs: groups, principles of action; principles of combining, dosage calculation. Prescribing standard chemotherapy.

Seminar

Modality	Location
-	-

Topics

Early and late complications of chemotherapy drugs.

Seminar

Modality	Location
-	-

Topics

Principles of radiotherapy in cases of haematological pathologies.

Seminar

Modality	Location
-	-

Topics

Therapeutic monoclonal antibodies, their application in haematology. Advantages and risks.

Seminar

Modality	Location
-	-

Topics

Haematological malignancies during pregnancy.

Seminar

Modality	Location
-	-

Topics

Prescribing immunosuppressive drugs and growth factors in cases of haematological tumours.

Total ECTS (Creditpoints):

9.00

Number of Residency Seminars:

Length (weeks):

Final Examination:

Residency exam (Theory and practice)

Bibliography

Required Reading

Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5. PMID: 30187086.

Yee C. Adoptive T cell therapy: points to consider. Curr Opin Immunol. 2018 Apr;51:197-203. doi: 10.1016/j.coi.2018.04.007. Epub 2018 May 2. PMID: 29730057.

Storch EK, Custer BS, Jacobs MR, Menitove JE, Mintz PD. Review of current transfusion therapy and blood banking practices. Blood Rev. 2019 Nov;38:100593. doi: 10.1016/j.blre.2019.100593. Epub 2019 Jul 25. PMID: 31405535.

Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019 Jun 28;452:66-70. doi: 10.1016/j.canlet.2019.02.048. Epub 2019 Mar 19. PMID: 30902563.

Kasi PM, Grothey A. Chemotherapy Maintenance. Cancer J. 2016 May-Jun;22(3):199-204. doi: 10.1097/PPO.0000000000000195. PMID: 27341599.

Voso MT, Ottone T, Lavorgna S, Venditti A, Maurillo L, Lo-Coco F, Buccisano F. MRD in AML: The Role of New Techniques. Front Oncol. 2019 Jul 23;9:655. doi: 10.3389/fonc.2019.00655. PMID: 31396481; PMCID: PMC6664148.

Press RD, Eickelberg G, Froman A, Yang F, Stentz A, Flatley EM, Fan G, Lim JY, Meyers G, Maziarz RT, Cook RJ. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol. 2019 Aug;94(8):902-912. doi: 10.1002/ajh.25514. Epub 2019 Jun 14. PMID: 31124175.

Ngai LL, Kelder A, Janssen JJWM, Ossenkoppele GJ, Cloos J. MRD Tailored Therapy in AML: What We Have Learned So Far. Front Oncol. 2021 Jan 15;10:603636. doi: 10.3389/fonc.2020.603636. PMID: 33575214; PMCID: PMC7871983.

Annen K, Olson JE. Optimizing platelet transfusions. Curr Opin Hematol. 2015 Nov;22(6):559-64. doi: 10.1097/MOH.0000000000000188. PMID: 26390163.

10.

Zeller MP, Al-Habsi KS, Heddle NM. Prophylactic platelet transfusions: should they be a treatment of the past? Curr Opin Hematol. 2014 Nov;21(6):521-7. doi: 10.1097/MOH.0000000000000087. PMID: 25203535.

11.

The Lancet Haematology. Updates on blood transfusion guidelines. Lancet Haematol. 2016 Dec;3(12):e547. doi: 10.1016/S2352-3026(16)30172-7. PMID: 27890071.

12.

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405. https://doi.org/10.1182/blood-2016-03-643544

13.

Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127:2672

14.

S.Lejniece. Klīniskā hematoloģija. Medicīnas Apgāds, 2020.

15.

Klīnisko analīžu rokasgrāmata. E.Gulbja laboratorija. Izdevējs E.Gulbja laboratorija, 2019.

16.

Alla Rivkina. Plūsmas citometrijas metode hematoloģisko slimību diagnostikā. SIA Medicīnas apgāds, 2019